| Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ... Nature medicine 20 (11), 1301-1309, 2014 | 1021 | 2014 |
| Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer L Bracci, G Schiavoni, A Sistigu, F Belardelli Cell Death & Differentiation 21 (1), 15-25, 2014 | 925 | 2014 |
| Consensus guidelines for the detection of immunogenic cell death O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ... Oncoimmunology 3 (9), e955691, 2014 | 833 | 2014 |
| Classification of current anticancer immunotherapies L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ... Oncotarget 5 (24), 12472, 2014 | 547 | 2014 |
| Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis G Schiavoni, A Sistigu, M Valentini, F Mattei, P Sestili, F Spadaro, ... Cancer research 71 (3), 768-778, 2011 | 385 | 2011 |
| Immunomodulatory effects of cyclophosphamide and implementations for vaccine design A Sistigu, S Viaud, N Chaput, L Bracci, E Proietti, L Zitvogel Seminars in immunopathology 33, 369-383, 2011 | 350 | 2011 |
| Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic … L Bracci, F Moschella, P Sestili, V La Sorsa, M Valentini, I Canini, ... Clinical Cancer Research 13 (2), 644-653, 2007 | 296 | 2007 |
| Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model E Proietti, L Bracci, S Puzelli, T Di Pucchio, P Sestili, E De Vincenzi, ... The Journal of Immunology 169 (1), 375-383, 2002 | 269 | 2002 |
| Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous-and allogeneic-stimulated … C Bocelli-Tyndall, L Bracci, G Spagnoli, A Braccini, M Bouchenaki, ... Rheumatology 46 (3), 403-408, 2007 | 242 | 2007 |
| Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of … G Schiavoni, F Mattei, T Di Pucchio, SM Santini, L Bracci, F Belardelli, ... Blood, The Journal of the American Society of Hematology 95 (6), 2024-2030, 2000 | 240 | 2000 |
| Type I IFNs control antigen retention and survival of CD8α+ dendritic cells after uptake of tumor apoptotic cells leading to cross-priming S Lorenzi, F Mattei, A Sistigu, L Bracci, F Spadaro, M Sanchez, M Spada, ... The Journal of Immunology 186 (9), 5142-5150, 2011 | 151 | 2011 |
| Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients P Nistico, I Capone, B Palermo, D Del Bello, V Ferraresi, F Moschella, ... International Journal of Cancer 124 (1), 130-139, 2009 | 115 | 2009 |
| Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level L Bracci, I Canini, S Puzelli, P Sestili, M Venditti, M Spada, I Donatelli, ... Vaccine 23 (23), 2994-3004, 2005 | 100 | 2005 |
| Combining type i interferons and 5-aza-2′-deoxycitidine to improve anti-tumor response against melanoma V Lucarini, C Buccione, G Ziccheddu, F Peschiaroli, P Sestili, R Puglisi, ... Journal of Investigative Dermatology 137 (1), 159-169, 2017 | 77 | 2017 |
| Type I interferons as vaccine adjuvants against infectious diseases and cancer L Bracci, V La Sorsa, F Belardelli, E Proietti Expert review of vaccines 7 (3), 373-381, 2008 | 74 | 2008 |
| Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15 C Bocelli-Tyndall, L Bracci, S Schaeren, C Feder-Mengus, A Barbero, ... Annals of the rheumatic diseases 68 (8), 1352-1359, 2009 | 64 | 2009 |
| Negatively charged gold nanoparticles as a dexamethasone carrier: stability in biological media and bioactivity assessment in vitro A Rossi, S Donati, L Fontana, F Porcaro, C Battocchio, E Proietti, I Venditti, ... RSC advances 6 (101), 99016-99022, 2016 | 57 | 2016 |
| Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus L Bracci, I Canini, M Venditti, M Spada, S Puzelli, I Donatelli, F Belardelli, ... Vaccine 24, S56-S57, 2006 | 52 | 2006 |
| Type I IFN regulate DC turnover in vivo F Mattei, L Bracci, DF Tough, F Belardelli, G Schiavoni European journal of immunology 39 (7), 1807-1818, 2009 | 50 | 2009 |
| Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B M Musella, A Guarracino, N Manduca, C Galassi, E Ruggiero, A Potenza, ... Nature immunology 23 (9), 1379-1392, 2022 | 49 | 2022 |
